Status:

COMPLETED

Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis

Lead Sponsor:

Alcon Research

Conditions:

Endogenous Anterior Uveitis

Eligibility:

All Genders

2+ years

Phase:

PHASE3

Brief Summary

The purpose of this study was to demonstrate that difluprednate 0.05% (Durezol) dosed 4 times daily is noninferior to prednisolone 1% (Pred Forte) dosed 8 times daily for the treatment of endogenous a...

Eligibility Criteria

Inclusion

  • Diagnosis of endogenous anterior uveitis in at least 1 eye.
  • The presence of \> 10 cells in the anterior chamber of at least one eye, and a flare score of \> 2 in that same eye.
  • Age 2 years or older on day of consent.
  • Negative urine pregnancy test on Day 0 for females of childbearing potential who are not at least 1 year post-menopausal or surgically sterilized.
  • Other protocol-defined inclusion criteria may apply.

Exclusion

  • Presence of endogenous anterior uveitis diagnosed for \> 2 weeks prior to enrollment in the study.
  • Presence of intermediate uveitis, posterior uveitis or panuveitis in either eye.
  • Instillation of any topical corticosteroid or NSAID in the study eye within 7 days of instillation of study drug.
  • History of glaucoma or clinically significant ocular hypertension in the opinion of the Investigator involving an IOP ≥ 21 millimeters mercury in either eye.
  • History of steroid-induced elevation of intraocular pressure.
  • Any confirmed or suspected active viral, bacterial or fungal keratoconjunctival disease in either eye.
  • History of glaucoma or clinically significant ocular hypertension in the opinion of the Investigator involving an intraocular pressure (IOP) \> 21 mmHg in either eye.
  • Corneal abrasion or ulceration in either eye.
  • Pregnancy or lactation.
  • Other protocol-defined exclusion criteria may apply.

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2011

Estimated Enrollment :

111 Patients enrolled

Trial Details

Trial ID

NCT01201798

Start Date

October 1 2010

End Date

August 1 2011

Last Update

November 15 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Contact Alcon Call Center

Fort Worth, Texas, United States, 76134